SCHEMBL13159461

SCHEMBL13159461

C=C(C(=O)OC(C)(C)CCOc1c2ccccc2cc2ccccc12)C(F)(F)F

nearest known ligand 0.33

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTB4R Q15722 3/20 0.33
CXCR2 P25025 2/20 0.33
KDM4E B2RXH2 3/20 0.33
ALDH1A1 P00352 3/20 0.33
HPGD P15428 3/20 0.33
MEN1 O00255 3/20 0.33
KMT2A Q03164 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GPR84 Q9NQS5 1/20 0.33
LMNA P02545 1/20 0.32
PRNP P04156 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
MTNR1A P48039 1/20 0.31
MTNR1B P49286 1/20 0.31
HDAC3 O15379 1/20 0.31
HDAC4 P56524 1/20 0.31
HDAC1 Q13547 1/20 0.31
HDAC7 Q8WUI4 1/20 0.31
HDAC2 Q92769 1/20 0.31
HDAC10 Q969S8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13159476 0.88 CASP1 (0.35) CXCR2KDM4EALDH1A1HPGDKMT2A
SCHEMBL13159331 0.87 CXCR2 (0.33) LTB4RCXCR2KDM4EALDH1A1HPGD
SCHEMBL13159464 0.86 GPR84 (0.38) LTB4RKDM4EALDH1A1HPGDGPR84
SCHEMBL13159526 0.86 CXCR2 (0.32) LTB4RCXCR2KDM4EALDH1A1HPGD
SCHEMBL13159459 0.84 KDM4E (0.49) KDM4EALDH1A1HPGDKMT2AHSD17B10
SCHEMBL13159465 0.82 KDM4E (0.33) KDM4EALDH1A1HPGDMEN1KMT2A
SCHEMBL13159356 0.80 ERN1 (0.36) LTB4RCXCR2KDM4EALDH1A1HPGD
SCHEMBL13159493 0.80 KDM4E (0.32) CXCR2KDM4EALDH1A1HPGDMEN1
SCHEMBL13159467 0.78 CASR (0.31)
SCHEMBL13159477 0.77 ATM (0.37) KDM4EALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8808960-B2 Compound and chemically amplified positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-08-19 US disclosed
US-8808960-B2 Compound and chemically amplified positive resist composition SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-08-19 US disclosed
US-20100233628-A1 COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed
US-20100233628-A1 COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100233628-A1 COMPOUND AND CHEMICALLY AMPLIFIED POSITIVE RESIST COMPOSITION HRH3, C9, H1-2 LTB4R 2498/4885CXCR2 1870/4885KDM4E 4077/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.